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Abstract
Rationale—Therapies which inhibit cholesteryl ester transfer protein (CETP) have failed to 
demonstrate a reduction in risk for coronary heart disease (CHD). Human deoxyribonucleic acid 
sequence variants that truncate the CETP gene may provide insight into the efficacy of CETP 
inhibition.
Objective—To test whether protein truncating variants (PTVs) at the CETP gene were associated 
with plasma lipid levels and CHD.
Methods and Results—We sequenced the exons of the CETP gene in 58,469 participants from 
12 case-control studies (18,817 CHD cases, 39,652 CHD-free controls). We defined PTV as those 
that lead to a premature stop, disrupt canonical splice-sites, or lead to insertions/deletions that shift 
frame. We also genotyped one Japanese-specific PTV in 27,561 participants from three case-
control studies (14,286 CHD cases, 13,275 CHD-free controls). We tested association of CETP 
PTV carrier status with both plasma lipids and CHD. Among 58,469 participants with CETP gene 
sequencing data available, average age was 51.5 years and 43% were female; 1 in 975 participants 
carried a PTV at the CETP gene. Compared to non-carriers, carriers of PTV at CETP had higher 
high-density lipoprotein cholesterol (HDL-C; effect size, 22.6 mg/dL; 95% confidence interval 
[CI], 18 to 27; P < 1.0×10−4), lower low-density lipoprotein cholesterol (LDL-C; −12.2 mg/dL; 
95% CI, −23 to −0.98; P = 0.033), and lower triglycerides (−6.3%; 95% CI, −12 to −0.22, P = 
0.043). CETP PTV carrier status was associated with reduced risk for CHD (summary odds ratio, 
0.70; 95% CI, 0.54 to 0.90; P = 5.1×10−3).
Conclusions—Compared with non-carriers, carriers of PTV at CETP displayed higher HDL-C, 
lower LDL-C, lower triglycerides, and lower risk for CHD.
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INTRODUCTION
In three randomized controlled clinical trials (RCTs), therapies which inhibit cholesteryl 
ester transfer protein (CETP) have failed to demonstrate a reduction in risk for coronary 
heart disease (CHD).1–3 Possible reasons for this failure include on-target lack of efficacy, 
off-target adverse effects of the small molecule, and/or randomized controlled trial design 
factors such as insufficient statistical power, concurrent statin therapy, or selection of study 
participants.4–6 A randomized trial of a fourth CETP inhibitor – anacetrapib – is ongoing.7
Studies of humans with naturally occurring genetic variation in genes encoding drug targets 
can provide insight into the potential efficacy and safety of therapeutic modulation targeting 
the gene product.8–10 Genetic studies of common, regulatory variants at the CETP gene 
region initially showed mixed results,11–15 but more recently, have converged on a consensus 
finding: alleles with lower CETP expression are associated with reduced CHD risk.16
Beyond common deoxyribonucleic acid (DNA) sequence variants, rare mutations that 
truncate a therapeutic target gene may be of particular value because they most closely 
mirror pharmacologic inhibition.8, 9, 17 Indeed, protein truncating variants (PTVs; i.e., 
nonsense, canonical splice-site, and frameshift mutations) at two therapeutic targets – NPC1 
Like Intracellular Cholesterol Transporter 1 (NPC1L1)9 and Proprotein Convertase 
Subtilisin/Kexin Type 9 (PCSK9)8 – are associated with lower low-density lipoprotein 
cholesterol (LDL-C) and reduced CHD risk. A therapeutic trial testing NPC1L1 inhibition 
was consistent with the human genetic findings,18 and a trial testing PCSK9 inhibition was 
consistent as well.19 Here, we tested if rare PTVs at the CETP gene were associated with 
plasma lipids and reduced odds of CHD.
METHODS
Study participants
First, we sequenced a total of 58,469 participants from the Myocardial Infarction Genetics 
(MIGen) Consortium of African, European, and South Asian ancestries (N=25,273), the 
DiscovEHR project of the Regeneron Genetics Center and the Geisinger Health System 
(DiscovEHR) of European ancestry (N=24,138),20 and TAICHI Consortium of East Asian 
ancestry (N=9,058)21 (Table 1). The MIGen Consortium consists of the Italian 
Atherosclerosis Thrombosis and Vascular Biology (ATVB) Study22, the Deutsches 
Herzzentrum München Myocardial Infarction Study (DHM)9, the Exome Sequencing 
Project Early-Onset Myocardial Infarction Study (ESP-EOMI)23, 24 of European and 
African ancestries, the Jackson Heart Study (JHS),25 the Leicester Acute Myocardial 
Infarction Peptide Study (Leicester),26 the Lübeck Myocardial Infarction Study (Lubeck),27 
the Ottawa Heart Study (OHS),28 the Precocious Coronary Artery Disease Study 
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(PROCARDIS),29 the Pakistan Risk of Myocardial Infarction Study (PROMIS),30 and the 
Registre Gironi del COR (REGICOR) Study.31
We also genotyped a Japanese-specific PTV at the CETP gene (rs5742907; IVS14+1G>A; 
splice-donor variant32) in a total of 27,561 Japanese participants from BioBank Japan 
(BBJ)33 and the Cardio-metabolic Genome Epidemiology Network and Coronary Artery 
Disease (CAGE-CAD) Stage 1 and Stage 2 studies (Table 1).34
All participants in the study provided written informed consent for genetic studies. The 
institutional review boards at the Broad Institute and each participating institution approved 
the study protocol.
Definition of CETP protein truncating variants
PTVs were defined as premature stop (nonsense), canonical splice-sites (splice-donor or 
splice-acceptor) including IVS14+1G>A (rs5742907), or insertion/deletion variants that 
shifted frame (frameshift). The positions of these PTVs were based on the GRGh37 human 
genome reference and the canonical transcript for CETP (Transcript ID: 
ENST00000200676).
Clinical characteristics, lipid measurements, and definition of CHD
A medical history and laboratory data for cardiovascular risk factors were obtained from all 
the study participants. Plasma total cholesterol, triglycerides, and high-density lipoprotein 
cholesterol (HDL-C) levels were determined enzymatically. LDL-C level was calculated 
using the Friedewald equation35, 36 for those with triglycerides <400 mg/dL. If triglycerides 
≥400 mg/dL, LDL-C level was directly measured, or set to missing. The effect of lipid-
lowering therapy at the time of lipid measurement was taken into account by dividing the 
measured total cholesterol and LDL-C levels by 0.8 and 0.7, respectively.37 HDL-C and 
triglyceride levels were not adjusted by lipid-altering medication use, and triglyceride levels 
were natural logarithm transformed for statistical analysis. CHD case and CHD-free control 
definitions of each study are in Supplemental Table I.
Sequencing and genotyping to characterize protein truncating variants
Whole exome sequencing of the MIGen Consortium was performed at the Broad Institute 
(Cambridge, MA, USA) as previously described.23 Sequencing reads were aligned to a 
human reference genome (build 37) using the Burrows–Wheeler Aligner-Maximal Exact 
Match algorithm. Aligned non-duplicate reads were locally realigned, and base qualities 
were recalibrated using the Genome Analysis ToolKit (GATK) software.38 Variants were 
jointly called using the GATK HaplotypeCaller program. The sensitivity of the Variant 
Quality Score Recalibration threshold was 99.6% for single nucleotide variants and 95% for 
insertion/deletion variants. All identified variants were annotated with the use of the Variant 
Effect Predictor software (version 82).39 The DiscovEHR project and TAICHI Consortium 
participants were exome-sequenced as previously described.20
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We also genotyped one splice-donor variant (IVS14+1G>A [rs5742907]) at the CETP gene 
using the multiplex PCR-based target sequencing in BBJ,40 or the TaqMan assay in CAGE-
CAD Stage 1 and Stage 2.
Statistical analysis
We tested the association of CETP PTV carrier status with lipid levels using linear 
regression adjusted by age, gender, study, and the first five principal components of ancestry 
(MIGen), or by age and gender (BBJ and CAGE-CAD Stage 1). Only CHD-free controls in 
each study were included in this assessment to minimize the effect of ascertainment bias. 
These data were meta-analyzed to calculate overall summary effect sizes with an inverse-
variance weighted fixed-effects model.
We tested the association of CETP PTV carrier status with CHD risk using a Cochran–
Mantel–Haenszel method without continuous correction. This method combines score 
statistics instead of Wald statistics and is useful for rare exposures when some observed odds 
ratios (OR) are zero. We removed ESP-EOMI and JHS from this analysis because no 
participant in these two studies carried a PTV at the CETP gene.
In an exploratory analysis, we evaluated if the effect of CETP PTVs on LDL-C could 
explain the reduction in CHD risk. We used an inverse-variance weighted model to draw a 
regression line with a 95% confidence interval (CI). Across four genes (APOB, NPC1L1, 
PCSK9, and CETP), we plotted the effect of DNA sequence variants in these genes on both 
LDL-C and CHD risk. The results for APOB, NPC1L1, and PCSK9 are derived from 
samples of the MIGen Consortium to draw a dose-response reference line. The results for 
CETP are summary estimate from all studies.
Statistical analyses were performed using R software version 3.2.3 (The R Project for 
Statistical Computing, Vienna, Austria).
RESULTS
Prevalence of CETP protein truncating variants
Sequencing of the 16 exons at the CETP gene was performed in 58,469 participants (18,817 
CHD cases and 39,652 CHD-free controls) from three projects: the MIGen Consortium, the 
DiscovEHR project, and TAICHI Consortium. Baseline characteristics of each study are 
shown in Table 1. A total of 23 PTVs were identified (ten premature stop, nine frameshifts, 
three splice-donor, and one splice-accepter variants). A total of 60 individuals carried one of 
the CETP PTVs, including 18 CHD cases (0.096%; 95% confidence interval (CI), 0.051 to 
0.14%) and 42 CHD-free controls (0.11%; 95% CI, 0.074 to 0.14%). Baseline 
characteristics by variant carrier status are shown in Supplemental Table II. We genotyped a 
Japanese-specific splice-donor variant (IVS14+1G>A [rs5742907]) in three studies from 
Japan and found the carrier frequency to be: BBJ, 0.78%; CAGE-CAD Stage1, 0.81%; and 
CAGE-CAD Stage2, 0.92%.
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Association of CETP protein truncating variants with plasma lipids
We assessed whether CETP PTV carrier status was associated with lipid levels (Table 2 and 
Supplemental Figure). We obtained plasma lipid profiles in 11,205 control participants from 
the MIGen Consortium and 6,955 control participants from BBJ and CAGE-CAD Stage 1. 
CETP PTV carrier status was associated with increased HDL-C (effect size, 22.6 mg/dL; 
95% CI, 18 to 27; P < 1×10−4), decreased LDL-C (−12.2 mg/dL; 95% CI, −23 to −0.98; P = 
0.033), and decreased triglycerides (−6.3%; 95% CI, −12 to −0.22; P = 0.043).
Association of CETP protein truncating variants with CHD
We evaluated the association of CETP PTV carrier status with CHD. Baseline characteristics 
and lists of CETP PTVs by case-control status in each study are shown in Supplemental 
Table III and Supplemental Table IV. In an analysis including a total of 82,722 participants, 
CETP PTV carrier status was significantly associated with lower risk for CHD (summary 
OR, 0.70; 95% CI, 0.54 to 0.90; P = 5.1×10−3) (Figure 1).
DNA sequence variants, LDL-C, and CHD risk across four genes
We explored whether the effect size of CETP PTV on CHD risk was consistent with its 
effect on LDL-C. We drew a dose-response reference line for CHD risk as a function of 
LDL-C change conferred by DNA sequence variants in three genes other than CETP. DNA 
sequence variants in APOB, NPC1L1, and PCSK9 associated with lower LDL-C also 
correlated with lower CHD risk. The effect of CETP PTV on CHD risk (30% reduction in 
risk) was consistent with the estimate based on the change in LDL-C (−12.2 mg/dl) (Figure 
2).
DISCUSSION
Across more than 80,000 participants, we evaluated whether CETP PTVs were associated 
with lipid levels and risk for CHD. About 1 in 975 participants carried a PTV at the CETP 
gene in sequencing studies, and compared with non-carriers, CETP PTV carriers exhibited 
significantly higher plasma HDL-C levels and lower LDL-C and triglyceride levels. The 
presence of a CETP PTV was also associated with decreased risk for CHD.
This evidence from rare human mutations that disrupt the CETP gene is consistent with 
earlier data on common, regulatory variants at the CETP locus. Common variants in the 
CETP have been associated with increased HDL-C, decreased LDL-C, decreased 
triglyceride levels,41 and reduced risk for CHD.13, 42–44 And recently, the statistical evidence 
for association of common CETP variants with CHD has exceeded a stringent genome-wide 
threshold.16 Exploratory analyses suggest that the effect of CETP PTV on lower CHD risk is 
consistent with lower LDL-C change conferred by these variants.
If human genetics shows loss of CETP function mutations to be associated with reduced 
CHD risk, why have three small molecule inhibitors of CETP function all failed to show 
lower CHD outcomes in randomized clinical trials? Several possibilities emerge. First, this 
could be due to off-target adverse effects of small molecule inhibitors. Torcetrapib, 
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dalcetrapib, and evacetrapib treatment all led to higher blood pressure in randomized 
controlled trials1–3; torcetrapib also led to hyperaldosteronism.1
Second, RCT design factors such as limited statistical power could play a role.4, 5 Human 
genetic evidence is supportive for apolipoprotein B-containing lipoproteins [low-density 
lipoprotein, triglyceride-rich lipoproteins, lipoprotein(a)] as causal factors for CHD whereas 
this is not the case for HDL-C.6 As such, any benefit from CETP inhibition may be solely 
due to the lowering of apolipoprotein B-containing lipoproteins. On background statin 
therapy, the LDL cholesterol and apolipoprotein B lowering effect is smaller, as shown in the 
ACCELERATE trial. 3 As such, it is unclear if RCTs were adequately powered to detect this 
benefit.
Third, statin therapy may modify the relationship of CETP activity and coronary disease. 
CETP promotes the transfer of cholesteryl esters from HDL to atherogenic apolipoprotein 
B-containing lipoproteins including LDL.4 If not cleared from the circulation, accumulation 
of such particles in the bloodstream promotes atherosclerotic progression. However, statins 
lead to substantial upregulation of hepatic LDL receptor density.45 In this context, 
apolipoprotein B-containing lipoproteins may be rapidly cleared from the circulation and 
excreted into the feces. CETP may therefore play a role in promoting reverse cholesterol 
transport, the process by which cholesterol is extracted from peripheral tissues (e.g. 
atherosclerotic plaque) and excreted from the body. Indeed, overexpression of CETP leads to 
enhanced reverse cholesterol transport via a LDL receptor dependent pathway in mouse 
models.46 Furthermore, individuals with increased on-statin CETP mass were protected 
from recurrent coronary events, particularly when the achieved LDL cholesterol was less 
than 80 mg/dl.47 Under this framework, pharmacologic CETP inhibition might prove less 
effective or potentially harmful among those in whom statin therapy leads to efficient 
clearance of apolipoprotein B-containing lipoproteins. However, the impact of CETP 
inhibition on reverse cholesterol transport has been questioned because the mouse studies 
might have been confounded by cholesterol pool size changes.48 Also, torcetrapib did not 
elevate fecal cholesterols or bile acids in both on- and off-statin individuals.49
Finally, phenotypic consequences of human PTVs reflect lifelong perturbation of a gene in 
every human tissue. In contrast, the results of RCTs reflect pharmacologic inhibition 
initiated later in life. As such, there are intrinsic limitations in using human mutations to 
anticipate efficacy and safety of pharmacologic manipulation.
These results should be interpreted in the context of study limitations. Definitions of CHD 
were different among studies. Cases in the MIGen Consortium and the DiscovEHR project 
were limited to only early-onset CHD while those in East Asian studies were not. Loss of 
CETP function alters the distribution of cholesterol and triglycerides in lipoproteins and as 
such, LDL-C levels estimated by the Friedewald equation might overestimate the reduction 
in participants harboring CETP PTVs. We only assessed four major lipid levels to evaluate 
effects of CETP PTV carrier status and other traits such as lipoprotein (a) or function of 
reverse cholesterol transport were unavailable. Results were somewhat stronger in 
participants from the Japanese genotyping studies, but the point estimates of the OR for 
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CHD were consistent between populations of Japanese and non-Japanese ancestries (0.69 
and 0.73, respectively).
Conclusions
In this meta analyses of data from 15 case-control studies, rare PTVs at the CETP gene were 
associated with higher HDL-C, lower LDL-C, lower triglycerides, and reduced risk for 
CHD.
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• Human DNA sequence variants that truncate a therapeutic target protein may 
provide insight into the efficacy of pharmacologic inhibition.
• It has been uncertain whether carriers of protein-truncating variants (PTVs) at 
the cholesteryl ester transfer protein (CETP) gene have altered plasma lipid 
levels and lower risk for coronary heart disease (CHD).
What New Information Does This Article Contribute?
• Carriers of a PTV at CETP had higher HDL cholesterol, lower LDL 
cholesterol, and lower triglycerides.
• CETP PTV carrier status was also associated with 30% reduced risk for CHD.
• Lifelong reduction in CETP function is associated with altered plasma lipids 
and a lower risk for CHD.
Therapies which inhibit CETP have failed to demonstrate a reduction in risk for CHD. 
Human DNA sequence variants that truncate a therapeutic target gene may provide 
insight into the efficacy of pharmacologic inhibition. We tested whether humans carrying 
PTVs at the CETP gene were associated with lipid levels, and were at reduced risk for 
CHD. We sequenced the exons of the CETP gene in 58,469 participants from 12 case-
control, and genotyped one Japanese-specific PTV in 27561 participants from three case-
control studies. PTVs at the CETP gene were defined as mutations that lead to a 
premature stop, disrupt canonical splice-sites, or lead to insertions/deletions that shift 
frame. In an analysis including more than 80,000 participants, carriers of a PTV at CETP 
had higher high-density lipoprotein cholesterol (+22.6 mg/dL), lower low-density 
lipoprotein cholesterol (−12.2 mg/dL), and lower triglycerides (−6.3%). CETP PTV 
carrier status was also associated with 30% reduced risk for CHD (summary odds ratio, 
0.70). In conclusion, compared with non-carriers, carriers of PTV at the CETP gene 
displayed higher HDL-C, lower LDL-C, lower triglycerides, and lower risk for CHD.
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Figure 1. Association of CETP protein truncating variant carrier status with risk for coronary 
heart disease
CETP protein truncating variant carrier status was associated with reduced risk for CHD. 
Each study column indicates [Study name] _[Ancestry].
Abbreviations: CHD, coronary heart disease; EAS, East Asian ancestry; EUR, European 
ancestry; OR, odds ratio; SAS, South Asian ancestry.
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Figure 2. Effects of DNA sequence variants in four genes on LDL-C and CHD risk
Dashed line denotes a dose-response reference line, with the 95% CI indicated by shadow. 
Error bar indicates CETP PTV 95% CIs of an effect size on LDL-C and odds ratio for CHD.
Abbreviations: CETP, cholesteryl ester transfer protein; CHD, coronary heart disease; LDL-
C, low-density lipoprotein cholesterol; PTV, protein truncating variant.
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